Web22 ago 2016 · ASG-5ME consists of a human IgG2 anti-SLC44A4 antibody conjugated through a cleavable linker to the microtubule-disrupting agent, monomethylauristatin E. It has potent anti-tumor activity in both... Web15 apr 2010 · ASG-5ME has a long (12 day) T 1/2 in mice. Taken together, these results support the clinical evaluation of ASG-5ME for treatment of pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.
A phase I study of ASG-5ME, a novel antibody-drug conjugate, in ...
WebSi tratta di uno studio clinico di fase 1, in aperto, con aumento della dose per sottovalutare la sicurezza e tollerabilità di ASG-5ME e identificare la dose massima tollerata nei pazienti … Web29 mar 2024 · ASG-5ME (Phase I) This ADC is targeted against the solute carrier receptor SLC44A4, and is a human IgG2 ant-SLC44A4 mAb linked to valine-citrulline-MMAE. It entered clinical trials at Phase I under Seattle Genetics but was discontinued for “commercial reasons”, with no further details being published. ime but
Abstract 4393: ASG-5ME is a novel antibody drug conjugate …
WebDownload Table Protein expression in prostate and pancreatic cancers from publication: The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive ... Web6 feb 2024 · ASG-5ME, an SLC44A4-targeting antibody carrying monomethyl auristatin E (MMAE), a microtubule-disrupting agent, was investigated in men with metastatic castration resistant prostate cancer. Methods The primary objective of this phase I study was to determine maximum tolerated dose (MTD) and recommended phase II dose. Web1 set 2012 · ASG-5ME is an antibody drug conjugate (ADC) comprised of a fully human antibody against SLC44A4, conjugated to the microtubule-disrupting agent monomethyl … ime bouchemaine
